Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (Q38473723)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 March 2009

Language	Label	Description	Also known as
English	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial	scientific article published on 28 March 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

circulatory system

1 reference

based on heuristic

inferred from title

Børge G. Nordestgaard

11

object named as

Børge G Nordestgaard

0 references

8

object named as

Peter Libby

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Wolfgang Koenig

7

object named as

Wolfgang Koenig

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1

object named as

Paul M Ridker

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

14

object named as

Robert J Glynn

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Jacques Genest jr.

4

object named as

Jacques Genest

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

John J. P. Kastelein

6

object named as

John Jp Kastelein

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Eleanor Danielson

2

object named as

Eleanor Danielson

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Alberto J Lorenzatti

9

object named as

Alberto J Lorenzatti

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Jean G Macfadyen

10

object named as

Jean G Macfadyen

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

JUPITER Trial Study Group

15

object named as

JUPITER Trial Study Group

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Francisco Ah Fonseca

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Antonio M Gotto

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

James Shepherd

12

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

James T Willerson

13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

language of work or name

0 references

publication date

28 March 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

373

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

9670

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1175-1182

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

C-reactive protein levels and outcomes after statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The immune response in atherosclerosis: a double-edged sword

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Toward immunomodulatory and anti-inflammatory properties of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960447-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60447-5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38473723&oldid=1761342979"